Table S2.
Six-month changes (after the ID) in HbA1c, body weight (kg), and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy in primary care practices in Germany
| Variables | N | Baseline ≤6 months before ID | 6 months after ID | Difference | P-value |
|---|---|---|---|---|---|
| Dapagliflozin monotherapy | |||||
| HbA1c (%) | 62 | 8.3 (1.7) | 7.8 (1.5) | −0.6 (1.3) | 0.001 |
| Body weight (kg) | 20 | 108.3 (30.8) | 102.2 (29.2) | −6.1 (16.3) | 0.042 |
| Systolic blood pressure (mmHg) | 40 | 137.1 (15.3) | 136.0 (18.6) | −1.1 (17.6) | 0.518 |
| Dapagliflozin + metformin | |||||
| HbA1c (%) | 69 | 8.3 (1.6) | 7.7 (1.4) | −0.6 (1.6) | 0.001 |
| Body weight (kg) | 21 | 102.7 (20.9) | 100.6 (21.2) | −2.1 (4.3) | 0.058 |
| Systolic blood pressure (mmHg) | 31 | 139.7 (15.2) | 135.4 (12.6) | −4.4 (17.2) | 0.129 |
| Dapagliflozin + insulin | |||||
| HbA1c (%) | 233 | 8.7 (1.6) | 7.9 (1.2) | −0.8 (1.6) | <0.001 |
| Body weight (kg) | 118 | 104.6 (22.5) | 102.8 (22.3) | −1.9 (6.4) | 0.007 |
| Systolic blood pressure (mmHg) | 180 | 137.2 (16.7) | 135.0 (17.3) | −2.2 (17.0) | 0.508 |
| Dapagliflozin + DPP-4 inhibitors | |||||
| HbA1c (%) | 298 | 8.5 (1.5) | 7.7 (1.2) | −0.8 (1.5) | <0.001 |
| Body weight (kg) | 68 | 95.9 (19.2) | 93.4 (18.3) | −2.5 (3.7) | <0.001 |
| Systolic blood pressure (mmHg) | 128 | 138.5 (18.2) | 136.2 (16.4) | −2.3 (16.8) | 0.227 |
Note: Data are presented as mean (SD). Bold text indicate that the effect is significant.
Abbreviations: DPP-4, dipeptidyl peptidase-4; ID, index date; SD, standard deviation; HbA1c, glycated hemoglobin.